TCIM
ANIK icon

TIAA CREF Investment Management’s Anika Therapeutics ANIK Stock Holding History

TIAA CREF Investment Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$892K Hold
29,499
– – ﹤0.01% 2377
2018
Q4 		$991K Sell
29,499
-1,601
-5% -$57.8K ﹤0.01% 2281
2018
Q3 		$1.31M Sell
31,100
-1,037
-3% -$41K ﹤0.01% 2323
2018
Q2 		$1.03M Sell
32,137
-2,098
-6% -$86.4K ﹤0.01% 2485
2018
Q1 		$1.7M Sell
34,235
-1,766
-5% -$99.8K ﹤0.01% 2185
2017
Q4 		$1.94M Sell
36,001
-2,416
-6% -$134K ﹤0.01% 2154
2017
Q3 		$2.23M Sell
38,417
-942
-2% -$49.2K ﹤0.01% 2111
2017
Q2 		$1.94M Sell
39,359
-7,532
-16% -$347K ﹤0.01% 2197
2017
Q1 		$2.04M Sell
46,891
-6,629
-12% -$316K ﹤0.01% 2138
2016
Q4 		$2.62M Sell
53,520
-1,778
-3% -$82.2K ﹤0.01% 2032
2016
Q3 		$2.65M Buy
55,298
+10,535
+24% +$520K ﹤0.01% 2023
2016
Q2 		$2.4M Sell
44,763
-2,165
-5% -$102K ﹤0.01% 2001
2016
Q1 		$2.1M Sell
46,928
-2,195
-4% -$89K ﹤0.01% 2040
2015
Q4 		$1.88M Sell
49,123
-23,750
-33% -$909K ﹤0.01% 2195
2015
Q3 		$2.32M Sell
72,873
-23,140
-24% -$807K ﹤0.01% 2050
2015
Q2 		$3.17M Buy
96,013
+1,942
+2% +$69.3K ﹤0.01% 1999
2015
Q1 		$3.87M Sell
94,071
-12,244
-12% -$495K ﹤0.01% 1807
2014
Q4 		$4.33M Sell
106,315
-3,050
-3% -$119K ﹤0.01% 1725
2014
Q3 		$4.01M Sell
109,365
-1,402
-1% -$60.6K ﹤0.01% 1771
2014
Q2 		$5.13M Buy
110,767
+4,746
+4% +$211K ﹤0.01% 1681
2014
Q1 		$4.36M Buy
106,021
+3,865
+4% +$144K ﹤0.01% 1717
2013
Q4 		$3.9M Buy
102,156
+24,519
+32% +$756K ﹤0.01% 1817
2013
Q3 		$1.86M Buy
77,637
+8,847
+13% +$199K ﹤0.01% 2246
2013
Q2 		$1.17M Buy
+68,790
New +$992K ﹤0.01% 2486

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

TIAA CREF Investment Management's ANIK Position: Q1 2019 in Review

TIAA CREF Investment Management held its Anika Therapeutics (ANIK) position steady in Q1 2019 at 29,499 shares worth $892K. The position accounts for ﹤0.01% of the portfolio, ranked #2377.

TIAA CREF Investment Management first reported a position in ANIK in Q2 2013 and has held it in 24 quarters since. The position peaked at $5.13M in Q2 2014. 157 funds tracked by Wall St. Rank hold ANIK as of Q1 2019.

  • TIAA CREF Investment Management held 29,499 shares of Anika Therapeutics worth $892K as of Q1 2019.
  • TIAA CREF Investment Management left its Anika Therapeutics share count unchanged in Q1 2019.
  • Anika Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2377 holding.
  • TIAA CREF Investment Management first reported a position in Anika Therapeutics in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Anika Therapeutics position peaked at $5.13M in Q2 2014.
  • 157 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.